Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.
Also called NCT01768702
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 315 participants
- Sponsor
- Celyad Oncology SA
- Registry
-
NCT01768702 -
2011-001117-13
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Bulgaria, Hungary, Israel, Italy, Poland, Serbia, Spain, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01768702. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2017-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
- Acronym
- CHART-1
- Condition
- Heart Failure
- Intervention (Biological)
- Injection of C3BS-CQR-1
- Intervention (Biological)
- Sham, no injection
- Lead sponsor
- Celyad Oncology SA
Record details
- Record id
cardio:ct-nct01768702- Content hash
2db75604de63a5d08b640e9fa08a2177242d279bd5a7b8f2d31b3e2cd4a23017